Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 5
2005 1
2006 7
2007 4
2008 6
2009 12
2010 11
2011 14
2012 10
2013 15
2014 11
2015 14
2016 16
2017 17
2018 9
2019 4
2020 11
2021 17
2022 21
2023 13
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.
Mei WJ, Wang XZ, Li YF, Sun YM, Yang CK, Lin JZ, Wu ZG, Zhang R, Wang W, Li Y, Zhuang YZ, Lei J, Wan XB, Ren YK, Cheng Y, Li WL, Wang ZQ, Xu DB, Mo XW, Ju HX, Ye SW, Zhao JL, Zhang H, Gao YH, Zeng ZF, Xiao WW, Zhang XP, Zhang X, Xie E, Feng YF, Tang JH, Wu XJ, Chen G, Li LR, Lu ZH, Wan DS, Bei JX, Pan ZZ, Ding PR. Mei WJ, et al. Among authors: wu xj. Ann Surg. 2023 Apr 1;277(4):557-564. doi: 10.1097/SLA.0000000000005780. Epub 2022 Dec 20. Ann Surg. 2023. PMID: 36538627 Free PMC article. Clinical Trial.
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial.
Xiao WW, Chen G, Gao YH, Lin JZ, Wu XJ, Luo HL, Lu ZH, Wang QX, Sun R, Cai PQ, Zhu CM, Liu M, Li JB, Wang YR, Jin Y, Wang F, Luo HT, Li CL, Pan ZZ, Xu RH. Xiao WW, et al. Among authors: wu xj. Cancer Cell. 2024 Sep 9;42(9):1570-1581.e4. doi: 10.1016/j.ccell.2024.07.004. Epub 2024 Aug 1. Cancer Cell. 2024. PMID: 39094560 Clinical Trial.
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS, Ren C, Li SS, Fong WP, Wu XJ, Xiao J, Li BK, Zheng Y, Ding PR, Chen G, Qiu MZ, Wang ZQ, Wang FH, Luo HY, Wang F, Wang XZ, Wang LY, Xie DJ, Chen T, Li LR, Lu ZH, Zhai XH, Liu TS, Yuan Y, Chen JQ, Tan Q, Pan ZZ, Wan DS, Zhang R, Yuan YF, Xu RH, Li YH. Wang DS, et al. Among authors: wu xj. PLoS Med. 2024 May 10;21(5):e1004389. doi: 10.1371/journal.pmed.1004389. eCollection 2024 May. PLoS Med. 2024. PMID: 38728364 Free PMC article. Clinical Trial.
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Yu JH, Xiao BY, Li DD, Jiang W, Ding Y, Wu XJ, Zhang RX, Lin JZ, Wang W, Han K, Kong LH, Zhang XK, Chen BY, Mei WJ, Pan ZZ, Tang JH, Zhang XS, Ding PR. Yu JH, et al. Among authors: wu xj. Lancet Oncol. 2024 Jul;25(7):843-852. doi: 10.1016/S1470-2045(24)00203-1. Epub 2024 Jun 6. Lancet Oncol. 2024. PMID: 38852601 Clinical Trial.
Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial.
Zhang RX, Wu XJ, Wan DS, Lin JZ, Ding PR, Liao LE, Lei J, Lu ZH, Li LR, Chen G, Kong LH, Wang FL, Zhang J, Fan WH, Jiang W, Zhou WH, Li C, Li Y, Li XY, Peng JH, Pan ZZ. Zhang RX, et al. Among authors: wu xj. Int J Surg. 2024 Apr 9;110(10):6622-31. doi: 10.1097/JS9.0000000000001301. Online ahead of print. Int J Surg. 2024. PMID: 38652147 Free PMC article.
Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S, Wang X, Zhuang Y, Bai S, Wu X, Ye Y, Luo H, Yu H, Wang Q, Chang H, Zeng Z, Cai P, Pan Z, Gao Y, Chen G, Xiao W. Liu S, et al. Cancer Med. 2023 Jun;12(12):13352-13360. doi: 10.1002/cam4.6034. Epub 2023 May 8. Cancer Med. 2023. PMID: 37156624 Free PMC article.
218 results